EFIC Grunenthal Grant attracts 29 applications of top-class young scientists

Brussels, Belgium / Aachen, Germany, 18 June 2007. Each year the European Federation of Chapters of the International Association for the Study of Pain (EFIC) in co-operation with the pharmaceutical company Grunenthal award young international scientists for their excellent work in carrying out innovative and exploratory clinical and human experimental pain research. This year 29 young researchers from 8 countries applied for funds totaling € 100,000.

“Each year the European Federation of Chapters of the International Association for the Study of Pain (EFIC) in co-operation with the pharmaceutical company Grunenthal award grant support in the field of pain science and medicine. These grants are intended to help young international scientists to carry out innovative and exploratory clinical and human experimental pain research at the highest level”, says Prof. Marshall Devor, Ph.D., Chairman of the EFIC Research Committee, Hebrew University of Jerusalem.

The application forms will now be reviewed by the EFIC Research Committee. Decisions on the candidates for sponsorships will be announced during this summer.

More information on the EFIC Grunenthal Grant is available at http://www.e-g-g.info.

About EFIC
The European Federation of Chapters of the International Association for the Study of Pain (EFIC) is a multidisciplinary professional organization in the field of pain science and medicine, made up of the 29 European chapters of IASP (International Association for the Study of Pain) representing 33 countries. Established in 1993, EFIC’s chapters represent close to 18,000 scientists, physicians, nurses, physiotherapists, psychologists and other healthcare professionals across Europe who study pain and treat patients in pain. EFIC’s aims are to advance research, education, clinical management and professional practice related to pain, and to serve as an authoritative, scientifically based resource concerning policy issues related to pain and its management.
http://www.efic.org/
About Grunenthal
Grunenthal is an expert in pain therapy and gynaecology and a pioneer in intelligent, user-friendly drug delivery technologies. The company discovers, develops, produces and markets high therapeutic value pharmaceuticals that contribute to patients’ ability to control their own lives. Grunenthal is an independent, family-owned German company operating with affiliates in 27 countries all over the world. Founded in 1946, the company employs 1,900 people in Germany and 4,800 worldwide. In 2006, Grunenthal achieved revenues of 813 million Euro.